Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its mid-December bear gap, after which it hit a Jan. 17, 52-week low of $78.17 amid ...

The Danish pharmaceutical company expects demand for obesity and diabetes drugs to rise, but forecasts sales growth to slow down this year. Read more.

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

Wegovy sales increased by more than 100% over 2024. But that wasn’t enough to satiate analysts who want to know why Novo Nordisk can’t access more patients, particularly in the U.S.

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig ...

Novo Nordisk (NYSE:NVO) forecasted slower sales growth for 2025, reflecting an expected moderation in demand for its ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...